Tectonic Therapeutic to Participate in March Investor Conferences

Rhea-AI Summary

Tectonic Therapeutic (NASDAQ: TECX), a clinical stage biotech company specializing in therapeutic proteins and antibodies for G-protein coupled receptors (GPCRs), has announced its participation in two investor conferences scheduled for March 2025.

The company will provide live webcasts of both events, accessible through the 'Events & Presentations' section of their website at www.tectonictx.com. Recordings will remain available for approximately 90 days after the conferences conclude.

The management team will conduct one-on-one meetings with investors during both conferences. Interested parties are advised to contact their TD Cowen and/or Leerink representatives to arrange meetings.

WATERTOWN, Mass., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced that company management will participate in two upcoming investor conferences taking place in March 2025.

TD Cowen 45th Annual Health Care Conference
Date:	March 5, 2025
Time:	9:50 AM EST
Location:	Boston, MA
Format:	Corporate Presentation
Presenter:	Alise Reicin, MD, President and Chief Executive Officer
Webcast:	Link

Leerink Partners Global Healthcare Conference
Date:	March 11, 2025
Time:	11:20 AM EDT
Location:	Miami, FL
Format:	Fireside Chat
Presenters:	Daniel Lochner, Chief Financial Officer, and Marc Schwabish, PhD, Chief Business Officer
Webcast:	Link

Both live webcasts can also be accessed under “Events & Presentations” on the Investors section of the Tectonic website at www.tectonictx.com. Once these conferences have concluded, a replay of the two webcasts will be available on the Company’s website for approximately 90 days.

The Tectonic management team will host one-on-one meetings during both conferences. Interested investors should contact their TD Cowen and/or Leerink representative to schedule meetings.

About Tectonic
Tectonic is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (“GPCRs”). Leveraging its proprietary technology platform called GEODe™ (GPCRs Engineered for Optimal Discovery), Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery and harness the human body to modify the course of disease. Tectonic focuses on areas of significant unmet medical need, often where therapeutic options are poor or nonexistent, as these are areas where new medicines have the potential to improve patient quality of life. Tectonic is headquartered in Watertown, Massachusetts. For more information, please visit www.tectonictx.com and follow on LinkedIn.

FAQ

When will Tectonic Therapeutic (TECX) participate in the March 2025 investor conferences?

Tectonic Therapeutic will participate in two investor conferences in March 2025, though specific dates were not disclosed in the announcement.

How long will the TECX March 2025 conference webcasts be available for replay?

The webcasts will be available for replay on Tectonic's website for approximately 90 days after the conferences conclude.

How can investors access Tectonic Therapeutic's March 2025 conference webcasts?

Investors can access the live webcasts through the 'Events & Presentations' section of Tectonic's website at www.tectonictx.com.

How can investors schedule one-on-one meetings with TECX management during the March 2025 conferences?

Investors should contact their TD Cowen and/or Leerink representatives to schedule one-on-one meetings with Tectonic's management team.

What is Tectonic Therapeutic's (TECX) primary research focus?

Tectonic Therapeutic focuses on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs).